Skip to main content
Equibles
MTNB logo

MTNB · Matinas BioPharma Holdings, Inc.

Track MTNB — free

Use MTNB with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about MTNB

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.23 +0.00 (+0.43%) At close · Aug 14
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We do not believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital requirements for a period of at least the next twelve months from the filing date of this Quarterly Report. As a result, substantial doubt exists about our ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$3.44M
Shares
14.69M

Matinas BioPharma Holdings, Inc. Earnings Call Transcripts

Every quarterly earnings call for Matinas BioPharma Holdings, Inc. (MTNB) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $95,833 −$5.45M '20 Q3 20-11-06 · $33,333 −$4.96M '21 Q1 21-05-10 · $1.06M −$5.92M '22 Q2 22-08-11 · $1.06M −$5.46M '22 Q3 22-11-02 LATEST · $1.10M −$5.51M '23 Q1 23-05-10
Earnings call
FY24 · Q2
2024-08-14
Matinas BioPharma Holdings, Inc. Q2 FY2024 Earnings Call
Positive tone MAT2203 Licensing Partnership Compassionate/Expanded Use Access Program LNC Platform and Oncology
Diluted EPS
$-1.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Matinas BioPharma Holdings, Inc. Q1 FY2024 Earnings Call
Positive tone MAT2203 partnership and Phase III ORALTO trial LNC platform in oncology Small oligonucleotide delivery (inflammation)
Diluted EPS
$-1.34
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-27
Matinas BioPharma Holdings, Inc. Q4 FY2023 Earnings Call
Confident tone MAT2203 ORALTO Phase III trial design and FDA agreement LNC platform expansion into oncology and inflammation Partnership discussions for MAT2203 commercialization
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Matinas BioPharma Holdings, Inc. Q3 FY2023 Earnings Call
Diluted EPS
$-1.39
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Matinas BioPharma Holdings, Inc. Q2 FY2023 Earnings Call
Diluted EPS
$-1.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Matinas BioPharma Holdings, Inc. Q1 FY2023 Earnings Call
Revenue
$1.10M
Diluted EPS
$-1.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-15
Matinas BioPharma Holdings, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Matinas BioPharma Holdings, Inc. Q3 FY2022 Earnings Call
Revenue
$1.06M
Diluted EPS
$-1.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Matinas BioPharma Holdings, Inc. Q2 FY2022 Earnings Call
Revenue
$1.06M
Diluted EPS
$-1.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Matinas BioPharma Holdings, Inc. Q1 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-08
Matinas BioPharma Holdings, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Matinas BioPharma Holdings, Inc. Q3 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
Matinas BioPharma Holdings, Inc. Q2 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Matinas BioPharma Holdings, Inc. Q1 FY2021 Earnings Call
Revenue
$33,333
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-29
Matinas BioPharma Holdings, Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-06
Matinas BioPharma Holdings, Inc. Q3 FY2020 Earnings Call
Revenue
$95,833
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Matinas BioPharma Holdings, Inc. Q2 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Matinas BioPharma Holdings, Inc. Q1 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-09
Matinas BioPharma Holdings, Inc. Q4 FY2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–19 of 19 earnings calls
Key facts CIK 1582554 CUSIP 576810303 13F (30d) 24 filings 24 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)